Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.

We calculated signature risk values using transcript-per-million (TPM)-normalized gene expression data available and observed non-significant HR 0.68 with p-value = 0.38, although an overall trend was preserved ( Figure 11G ).

also in 4,871 other papers